CONMED (NYSE:CNMD) Releases FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.480-4.530 for the period, compared to the consensus estimate of 4.470. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CNMD. Piper Sandler cut their target price on CONMED from $80.00 to $68.00 and set an “overweight” rating on the stock in a research report on Thursday, July 31st. Weiss Ratings reissued a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $59.80.

CONMED Trading Down 4.8%

NYSE:CNMD opened at $42.32 on Thursday. The stock’s 50 day moving average price is $48.63 and its 200 day moving average price is $51.99. The company has a market capitalization of $1.31 billion, a PE ratio of 11.96, a P/E/G ratio of 1.59 and a beta of 1.14. The company has a quick ratio of 1.00, a current ratio of 2.23 and a debt-to-equity ratio of 0.88. CONMED has a 52-week low of $42.50 and a 52-week high of $78.00.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $337.93 million for the quarter, compared to the consensus estimate of $334.76 million. CONMED had a return on equity of 14.43% and a net margin of 8.31%.The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.05 EPS. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. On average, research analysts anticipate that CONMED will post 4.35 EPS for the current year.

Insider Transactions at CONMED

In related news, Director Charles Farkas sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $53.52, for a total transaction of $107,040.00. Following the transaction, the director owned 14,859 shares in the company, valued at $795,253.68. This trade represents a 11.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.10% of the stock is owned by corporate insiders.

Institutional Trading of CONMED

A number of institutional investors have recently modified their holdings of the business. Public Sector Pension Investment Board boosted its stake in shares of CONMED by 7.7% in the second quarter. Public Sector Pension Investment Board now owns 105,513 shares of the company’s stock valued at $5,495,000 after buying an additional 7,530 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of CONMED by 107.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,248 shares of the company’s stock valued at $221,000 after buying an additional 2,205 shares in the last quarter. State of Tennessee Department of Treasury boosted its stake in shares of CONMED by 17.4% in the second quarter. State of Tennessee Department of Treasury now owns 15,498 shares of the company’s stock valued at $807,000 after buying an additional 2,302 shares in the last quarter. Moore Capital Management LP purchased a new stake in shares of CONMED in the second quarter valued at approximately $677,000. Finally, Holocene Advisors LP boosted its stake in shares of CONMED by 60.0% in the second quarter. Holocene Advisors LP now owns 50,370 shares of the company’s stock valued at $2,623,000 after buying an additional 18,894 shares in the last quarter.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.